Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience MCA Manrique, JM Martínez, JG González, FJA Afonso, ML Quintela, ... Translational lung cancer research 7 (3), 404, 2018 | 64 | 2018 |
Assessment of a new ROS1 immunohistochemistry clone (SP384) for the identification of ROS1 rearrangements in patients with non–small cell lung carcinoma: the ROSING study E Conde, S Hernandez, R Martinez, B Angulo, J De Castro, ... Journal of Thoracic Oncology 14 (12), 2120-2132, 2019 | 63 | 2019 |
Molecular basis of hypertension side effects induced by sunitinib G Aparicio-Gallego, FJ Afonso-Afonso, L León-Mateos, JL Fírvida-Pérez, ... Anti-Cancer Drugs 22 (1), 1-8, 2011 | 55 | 2011 |
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish … B Pérez-Valderrama, JAA Arija, AR Sánchez, AP Marín, PB García, ... Annals of Oncology 27 (4), 706-711, 2016 | 42 | 2016 |
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study J Ruiz-Bañobre, A Molina-Díaz, O Fernández-Calvo, N Fernández-Núñez, ... ESMO open 6 (2), 100090, 2021 | 38 | 2021 |
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant … M Casarrubios, M Provencio, E Nadal, A Insa, ... Journal for immunotherapy of cancer 10 (9), 2022 | 29 | 2022 |
Recent advances in genitourinary tumors: a review focused on biology and systemic treatment AG Del Alba, JÁ Arranz, J Puente, MJ Méndez-Vidal, E Gallardo, ... Critical reviews in oncology/hematology 113, 171-190, 2017 | 23 | 2017 |
PD-(L) 1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: a pairwise meta-analysis J García-González, J Ruiz-Bañobre, FJ Afonso-Afonso, ... Journal of Clinical Medicine 9 (7), 2093, 2020 | 20 | 2020 |
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study J Casal Rubio, JL Firvida-Perez, M Lazaro-Quintela, FJ Barón-Duarte, ... Cancer chemotherapy and pharmacology 73, 451-457, 2014 | 14 | 2014 |
Radium-223 dichloride: a new paradigm in the treatment of prostate cancer U Anido Herranz, O Fernandez Calvo, FJ Afonso Afonso, ... Expert Review of Anticancer Therapy 15 (3), 339-348, 2015 | 13 | 2015 |
Renal primary angiosarcoma B Carnero López, I Fernández Pérez, JA Carrasco Alvarez, ... Clinical and Translational Oncology 9, 806-810, 2007 | 13 | 2007 |
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor … JL González-Larriba, M Lázaro-Quintela, M Cobo, M Dómine, M Majem, ... Translational Lung Cancer Research 6 (Suppl 1), S21, 2017 | 11 | 2017 |
carcinoma tímico J Castellanos Diez, M Lázaro Quintela, M Jorge Fernández, ... Guía práctica de tumores poco frecuentes. Lázaro Quintela M, Jorge Fernández …, 2003 | 10 | 2003 |
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study N Lainez, J García-Donas, E Esteban, J Puente, MI Sáez, E Gallardo, ... BMC cancer 16, 1-10, 2016 | 9 | 2016 |
Preferences for renal cell carcinoma pharmacological treatment: a discrete choice experiment in patients and oncologists O Fernández, M Lázaro-Quintela, G Crespo, D Soto de Prado, Á Pinto, ... Frontiers in Oncology 11, 773366, 2022 | 8 | 2022 |
Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor ML Quintela, LL Mateos, SV Estévez, OF Calvo, UA Herranz, FJA Afonso, ... Cancer Treatment Reviews 41 (3), 247-253, 2015 | 8 | 2015 |
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate … MA Climent, A Font, I Durán, J Puente, MJ Méndez-Vidal, MI Sáez, ... European Journal of Cancer 175, 110-119, 2022 | 7 | 2022 |
New clinical trials regulation in Spain: analysis of royal decree 1090/2015 M Martin Jimenez, A Calvo Ferrandiz, J Aparicio Urtasun, ... Clinical and Translational Oncology 19, 291-300, 2017 | 7 | 2017 |
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer U Anido-Herranz, N Fernández-Núñez, J Afonso-Afonso, ... Clinical and Translational Oncology 21, 249-258, 2019 | 6 | 2019 |
Prostate cancer perspectives after chaarted: optimizing treatment sequence SV Estévez, UA Herranz, OF Calvo, FJA Afonso, LS Couto, ML Quintela, ... Critical Reviews in Oncology/Hematology 107, 119-127, 2016 | 6 | 2016 |